About this trial
Type 2 diabetes (T2D) mellitus is a challenge for health care systems as the numbers increases constantly. In 2014, 422 million people had been living with diabetes worldwide. The absolute numbers of people with prediabetes have also grown substantially over 25 years worldwide. In Germany, about 10% of the population has T2D and another 21 % of the population has prediabetes.Overall, 16% of all deaths in Germany are attributable to type 2 diabetes. Macro- and microvascular complications of diabetes imply a significant threat for the patients and are already present in the prediabetic state. Short term and long term complications, the burden of treatment, and reduced quality of life are major burdens of the disease. Accumulating data indicate that currently recommended therapeutic diet regimens in patients with obesity and diabetes are not sustainable on the long term. Novel concepts are therefore urgently needed.
T2D occurs when insulin secretion from pancreatic beta-cells cannot sufficiently be increased to compensate for insulin resistance. Causes of beta-cell dysfunction are heterogeneous. In addition, the most important determinants of diabetes remission are the extend of weight loss and restoration of beta-cell function. In the course of diabetes progression, the inability to recover insulin secretion might identify the state of no return to normal glucose tolerance. It is therefore crucial to improve insulin secretion in treatment and prevention of diabetes. Up to now lifestyle intervention trials in prediabetes or pharmacological intervention trials in diabetes did not show improvement of insulin secretion after intervention. However, one recent small human trial shows that intermittent fasting (early time restricted fasting) is able to improve insulin secretion.Currently, there are no trials that examine the effect of intermittent fasting in individuals with a broad range of impaired glucose metabolism (from prediabetes to diabetes). Recently novel subtypes of diabetes and prediabetes with high risk for the early manifestation of diabetes complications have been identified. Currently, prevention strategies for this high risk individuals have not been examined yet. We will study for the first time the effectiveness of 4 weeks intermittent fasting on changes in insulin secretion capacity in subphenotypes of diabetes and in prediabetes.
Eligibility criteria
Qualifiers
Body mass index (BMI) between 25 - 40 kg/m²
Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures.
Subjects with prediabetes (IFG and/or IGT, HbA1c 5,4 % - 6,4 %, subphenotype cluster 3 or 5) or
Subjects with type 2 diabetes mellitus (diagnosed <5 years prior to screening), HbA1c 6.0% - 9.5%, not receiving insulin or thiazolidinediones, and with an appropriate washout period for all other antidiabetic medications)
Disqualifiers
Subjects with diabetes mellitus type 1 (GAD-, IA2-AB positive)
Women during pregnancy and lactation
Treamtent with any medication effecting on glucose metabolism like anti-diabetic drugs or steroids
Subjects with a haemoglobin (Hb) ≤ 11.5 g/dl (for males) and Hb ≤ 10.5 g/dl (for females) at screening
Trial design
Treatments tested in this trial
- Intermittent fasting
- Control diet
Treatment groups
Sponsors and collaborators
University Hospital Tuebingen
Lead sponsor
German Institute of Human Nutrition
Collaborator
Charite University, Berlin, Germany
Collaborator
University Hospital Carl Gustav Carus
Collaborator
University of Leipzig
Collaborator
Ludwig-Maximilians - University of Munich
Collaborator
University Hospital Heidelberg
Collaborator
University of Luebeck
Collaborator
German Diabetes-Center, Leibniz-Institut in Düsseldorf
Collaborator
German Center for Diabetes Research
Collaborator